83 related articles for article (PubMed ID: 17477790)
1. Weak linkage in hepatitis C PePHD: identification of mutation prone point that can lead to failure of antiviral therapy for prevention of hepatocellular carcinoma.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(1):139-40. PubMed ID: 17477790
[TBL] [Abstract][Full Text] [Related]
2. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
[TBL] [Abstract][Full Text] [Related]
4. The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha.
Cochrane A; Orr A; Shaw ML; Mills PR; McCruden EA
J Infect Dis; 2000 Nov; 182(5):1515-8. PubMed ID: 11023475
[TBL] [Abstract][Full Text] [Related]
5. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
Gaudy C; Lambelé M; Moreau A; Veillon P; Lunel F; Goudeau A
J Clin Microbiol; 2005 Feb; 43(2):750-4. PubMed ID: 15695675
[TBL] [Abstract][Full Text] [Related]
6. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the E2-PePHD region of hepatitis C virus type 1b in patients with hepatocellular carcinoma.
Bagaglio S; De Mitri MS; Lodrini S; Paties C; Cassini R; Bianchi G; Bernardi M; Lazzarin A; Morsica G
J Viral Hepat; 2005 May; 12(3):243-50. PubMed ID: 15850464
[TBL] [Abstract][Full Text] [Related]
8. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
9. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
[TBL] [Abstract][Full Text] [Related]
10. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
Polyak SJ; Nousbaum JB; Larson AM; Cotler S; Carithers RL; Gretch DR
J Infect Dis; 2000 Aug; 182(2):397-404. PubMed ID: 10915068
[TBL] [Abstract][Full Text] [Related]
11. Weak linkage in androgen receptor: identification of mutation-prone points.
Wiwanitkit V
Fertil Steril; 2009 Jan; 91(1):e1-3. PubMed ID: 17936280
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma.
Vescovo T; Refolo G; Vitagliano G; Fimia GM; Piacentini M
Clin Microbiol Infect; 2016 Oct; 22(10):853-861. PubMed ID: 27476823
[TBL] [Abstract][Full Text] [Related]
13. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
[TBL] [Abstract][Full Text] [Related]
14. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
[No Abstract] [Full Text] [Related]
15. Identification of mutation-prone points in bile salt export pump.
Wiwanitkit V
HPB (Oxford); 2007; 9(6):444-6. PubMed ID: 18345292
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
Hofmann WP; Zeuzem S; Sarrazin C
J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients.
Zabek P; Opoka-Kegler J; Baka M; Dyda T; Stańczak GP; Stańczak JJ
Przegl Epidemiol; 2013; 67(3):411-3, 521-3. PubMed ID: 24340552
[TBL] [Abstract][Full Text] [Related]
19. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.
Nakamoto S; Imazeki F; Fukai K; Fujiwara K; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
J Hepatol; 2010 Jan; 52(1):72-8. PubMed ID: 19910070
[TBL] [Abstract][Full Text] [Related]
20. Designing a low-cost drug resistance database for viral hepatitis.
Kuiken C
Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
